Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 151-156 , April 2010

Controversies in the management of fever in the neutropenic cancer patient

  • Matthew D. Seftel

      Affiliations

    • Corresponding Author InformationAddress: ON2081 CancerCare Manitoba, 675 Mcdermot Avenue, Winnipeg, Manitoba, Canada R3E0V9. Tel.: +1 204 787 3594; fax: +1 204 786 0196.

References 

  1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  2. Ciuraru NB, Braunstein R, Sulkes A, Stemmer SM. The influence of mucositis on oral thermometry: when fever may not reflect infection. Clin Infect Dis. 2008;46:1859–1863
  3. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–2395
  4. Fuchs M, Franklin J, Klimm B, et al. Mortality during treatment of patients with advanced Hodgkin’s lymphoma undergoing dose escalated BEACOPP chemotherapy: an analysis of the german Hodgkin study group (GHSG). ASH Annual Meeting Abstracts. Blood. 2005;106:2668
  5. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402–2409
  6. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453
  7. Hamalainen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences. Leuk Lymphoma. 2008;49:495–501
  8. Mato AR, Luger S, Alison LW, et al. Serum lactic acid (LA) as a predictor of septic shock in patients with hematologic malignancies (HM) who develop febrile neutropenia. ASH Annual Meeting Abstracts. Blood. 2008;112:666
  9. Klastersky J, Paesmans M. Institut Jules Bordet, Centre des Tumeurs de l’Universite Libre de Bruxelles. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer. 2007;15:477–482
  10. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051
  11. Qx MD Hematology. Available from: <http://www.qxmd.com/hematology/MASCC-Febrile-Neutropenia-Risk.php> (accessed 27.02.09).
  12. Paul M, Gafter-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988–2004. Isr Med Assoc J. 2007;9:424–429
  13. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;341:312–318
  14. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341:305–311
  15. Innes HE, Smith DB, O’Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003;89:43–49
  16. Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer. 2008;16:1017–1023
  17. Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004;54:29–37
  18. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2006;57:176–189
  19. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–348
  20. US Food and Drug Administration Center for Drug Evaluation and Research. Early communication about an ongoing safety review. Cefepime (marketed as Maxipime). Available from: <http://www.fda.gov/Cder/Drug/early_comm/cefepime.htm> (accessed 27.02.09).
  21. Nguyen TD, Williams B, Trang E. Cefepime Therapy and All-Cause Mortality. Clin Infect Dis. 2009;48:902–904
  22. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 2006;43:447–459
  23. Harter C, Schulze B, Goldschmidt H, et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 2006;37:373–379
  24. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1201–1207
  25. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326:1111
  26. Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005;(3):CD003914.
  27. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002;34:1524–1529
  28. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer. 2006;107:1743–1751
  29. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987
  30. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–998
  31. Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol. 2007;25:4821–4828
  32. Smith TJ, Khatcheressian J, Lyman GH, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  33. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–3167
  34. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005;23:7974–7984
  35. Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24:2991–2997
  36. Herbst C, Naumann F, Kruse EB, et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009;(1):CD007107.
  37. Herbst C, Naumann F, Herbst O, Bohlius J, Juni P, Engert A. Preventing infections in cancer patients: antibiotics, hematopoietic growth factors or both? A network analysis. ASH Annual Meeting Abstracts. Blood. 2008;112:1315
  38. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2007;59:5–22

PII: S1473-0502(10)00012-1

doi: 10.1016/j.transci.2010.01.011

Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 151-156 , April 2010

Article Tools